American Association for Cancer Research
15357163mct160252-sup-165482_1_supp_3598118_11vn7p.doc (29 kB)

Supplementary data from The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells

Download (29 kB)
journal contribution
posted on 2023-04-03, 15:24 authored by Raphaël Bergès, Aurélie Tchoghandjian, Stéphane Honoré, Marie-Anne Estève, Dominique Figarella-Branger, Felix Bachmann, Heidi A. Lane, Diane Braguer

Materials and methods: EB1 Western blot analysis GBM stem cells were lysed (lysis buffer: Tris 50 mM pH 8.0, NaCl 250 mM, Triton-X100 1%, SDS 0.1% with a cocktail of proteases and phosphatases inhibitors added freshly (all from Sigma-Aldrich). Thirty µg of total protein lysate were loaded onto a 12% SDS-PAGE gel. Nitrocellulose membrane (Bio-Rad laboratories, Marnes la Coquette, France) was blocked with 5% milk (powder) in Phosphate Buffer Saline (PBS) (Life technologies)-Tween (Sigma-Aldrich) pH 7.4 for 1 h and then incubated in PBS-Tween 0.1%-5% milk solution with mouse anti-EB1 antibody (clone 5, BD Biosciences, Le pont de Claix, France) (1/1000) and mouse α-tubulin (clone DM1A, Sigma Aldrich). After washing, membranes were incubated with anti-mouse peroxydase-conjugated secondary antibodies (Jackson Immunoresearch, Baltimore, USA) for 1 h. The bound antibodies were then detected using chemiluminescence detection kit (Millipore, Saint Quentin en Yvelines, France). Signals were recorded with G:BOX (Syngene/Ozyme, Saint Quentin en Yvelines, France ) and quantification was done with Image J software. Immunofluorescence analysis Indirect immunofluorescence was performed as previously described (15). Briefly, cells were fixed for 5 min with cold methanol (-20{degree sign}C), incubated with the anti-EB1 antibody 1/100 for 1 h and anti-mouse antibody Alexa 568 nm (Molecular Probes) 1/200; and FITC-coupled anti-α-tubulin antibody (clone DM1A; Sigma-Aldrich) 1/200 for 1 h at room temperature in the presence of DAPI for nuclear staining. For GFAP staining, cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton-X100 for 10 minutes. Primary antibody against GFAP (rabbit IgG, 10€‰Î¼g/ml, Dako) was incubated overnight at 4€‰{degree sign}C. Secondary antibody, Texas-red Goat anti-rabbit IgG (H+L) was purchased from Jackson Immunoresearch (Newmarket, UK), and was incubated for 1 h. Cells were analyzed using a Leica DM-IRBE microscope at a magnification of x100. Real-time quantitative PCR RNA samples were processed using a LightCycler 480 instrument (Roche Applied Science) and a LightCycler 480 SYBR Green I Master Mix (Roche Applied Science). Briefly, total DNA-free RNA (1 μg) was reverse-transcribed into cDNA using 1 μg of random hexamers and Superscript II reverse transcriptase as recommended by the manufacturer (Invitrogen Life Technologies, Cergy Pontoise, France). Measurements were performed in triplicate for each sample, and relative expression ratios of target gene transcripts (GFAP, TUBB3, CNP) and reference gene transcripts (18S, GAPDH, and ACTB) were calculated using qPCR efficiencies and cycle threshold (Ct) deviations of tumor and normal adult brain samples (control: Agilent Technologies) (25). RNA expression levels in GBM CSLCs were subsequently expressed as percentages compared to normal adult human brain samples corresponding to 100% of expression. Forward and reverse primers used for each gene are listed in Supplemental Table 1. Supplementary Table 1: Sequences of primers used in RT-qPCR Supplementary Figure 1: Chemical structure of BAL27862 and BAL101553 Supplementary Figure 2: Modulation of EB1 expression in GBM6 cells using siRNA or shRNA against EB1. (A) Western blot analysis of EB1 in GBM6 shEB1 clones (GBM6 shEB1, GBM6 shEB1#2), in GBM6 GFP shEB1 clone and in control clones (GBM6 wt, GBM6 sh0 and GBM6 GFP sh0). Ratios EB1/tubulin, relative to controls, from at least three independent experiments are presented under the blots. (B) Analysis of EB1 expression by Western blot of GBM6 wt or treated with siRNA against EB1 (GBM6 siEB1) or siRNA control (GBM6 si0). (C) Immunofluorescence staining of tubulin (green) and EB1 (red) in GBM6 wt, GBM6 si0 and GBM6 siEB1. Bar = 10 μm.



Investissements d'Avenir

DGOS (SIRIC label) INCa-DGOS-Inserm


Basilea Pharmaceutica International Ltd



Glioblastoma patients have limited treatment options. Cancer stem-like cells (CSLC) contribute to glioblastoma invasiveness and repopulation; hence, they represent promising targets for novel therapies. BAL101553 is a prodrug of BAL27862, a novel microtubule-destabilizing agent inhibiting tumor cell proliferation through activation of the spindle assembly checkpoint, which is currently in phase I/II clinical development. Broad anticancer activity has been demonstrated against human cancer models, including tumors refractory to conventional treatments. We have shown that overexpression of microtubule + end-binding 1-protein (EB1) correlates with glioblastoma progression and poor survival. Here, we show that BAL27862 inhibits the growth of two glioblastoma CSLCs. As EB1 is overexpressed in the CSLC line GBM6, which displays a high tumorigenicity and infiltrative pattern of migration in vivo, we investigated drug activity on GBM6 according to EB1 expression. BAL27862 inhibited migration and colony formation at subcytotoxic concentrations in EB1-expressing control cells (GBM6-sh0) but only at cytotoxic concentrations in EB1-downregulated (GBM-shE1) cells. Three administrations of BAL101553 were sufficient to provoke an EB1-dependent survival benefit in tumor-bearing mice. Patterns of invasion and quantification of tumor cells in brain demonstrated that GBM6-sh0 cells were more invasive than GBM6-shEB1 cells, and that the antiproliferative and anti-invasive effects of BAL101553 were more potent in mice bearing control tumors than in EB1-downregulated tumors. This was associated with inhibition of stem cell properties in the GBM6-sh0 model. Finally, BAL27862 triggered astrocytic differentiation of GBM6 in an EB1-dependent manner. These results support the potential of BAL101553 for glioblastoma treatment, with EB1 expression as a predictive biomarker of response. Mol Cancer Ther; 15(11); 2740–9. ©2016 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager